---
title: "CITIC Construction Investment: Maintains \"Buy\" rating on YUYUE MEDICAL, overseas business is expected to maintain rapid growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/242340686.md"
description: "CITIC Construction Investment Securities maintains a \"Buy\" rating on YUYUE MEDICAL, believing that its annual report performance meets expectations, with Q1 revenue slightly exceeding expectations and profits in line with expectations. It is anticipated that the recovery of domestic consumer demand and the increase in market share will drive steady growth in domestic business. At the same time, overseas business is expected to grow rapidly due to channel layout and brand building. In the short term, core businesses such as respiratory therapy and blood glucose management have strong competitiveness; in the medium to long term, the improvement of health awareness and the iteration of new products will consolidate its leading position in the domestic market and enhance its global market share"
datetime: "2025-05-29T07:37:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/242340686.md)
  - [en](https://longbridge.com/en/news/242340686.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/242340686.md)
generator: "portal-rs"
---

# CITIC Construction Investment: Maintains "Buy" rating on YUYUE MEDICAL, overseas business is expected to maintain rapid growth

CITIC Construction Investment Securities' research report pointed out that YUYUE MEDICAL's annual report performance met expectations, with Q1 revenue slightly exceeding expectations and profit in line with expectations. Looking ahead to the whole year, with the recovery of domestic consumer demand and the continuous increase in the company's market share, the company's domestic business is expected to maintain a steady growth trend; as the company continues to accelerate its overseas channel layout and brand building, its overseas business is expected to maintain rapid growth. In the short term, the company's core businesses such as respiratory therapy and blood glucose management have strong market competitiveness. In the medium to long term, with the improvement of public health awareness and the continuous iteration and enrichment of the company's new products, the company's leading position in the domestic home medical device platform is expected to remain solid, and its global market share is expected to increase. Maintain a "Buy" rating

### Related Stocks

- [002223.CN](https://longbridge.com/en/quote/002223.CN.md)
- [06066.HK](https://longbridge.com/en/quote/06066.HK.md)

## Related News & Research

- [Chinese Pharma Companies Plan Hong Kong Listings](https://longbridge.com/en/news/297979501.md)
- [An Insider At Sun International Lowered Their Holding Recently](https://longbridge.com/en/news/298260368.md)
- [Viromed Medical’s Heike Perbandt, closely associated with managing body member Uwe Perbandt, sells shares for EUR 52,000](https://longbridge.com/en/news/298227013.md)
- [SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals](https://longbridge.com/en/news/298195637.md)
- [Eurofins Scientific CEO-controlled Analytical Bioventures buys EUR 218,458 of shares](https://longbridge.com/en/news/298342552.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**